Serum Zta antibody of Epstein–Barr virus exerts potential function in the diagnosis of nasopharyngeal cancer

详细信息    查看全文

• 作者：Xiaoyan Zhang (1)
  Yun Zhang (1)
  Yunqiang Nie (2)
  Shoufeng Wang (1)
  Yanlin Chen (3)
  Dezhong Sun (3)
  
• 关键词：Nasopharyngeal cancer ; Epstein–Barr virus ; Zta ; Diagnosis ; Meta ; analysis
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：35
• 期：7
• 页码：6879-6886
• 全文大小：1,856 KB
• 参考文献：1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA. Cancer J Clin. 2002;55:74-08. CrossRef
  2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765-7. CrossRef
  3. O'Neil JD, Owen TJ, Wood VH, Date KL, Valentine R, Chukwuma MB, et al. Epstein–Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol. 2008;89:2833-2. CrossRef
  4. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976;17:1-. CrossRef
  5. Old LJ, Boyse EA, Oettgen HF, de Harven E, Geering G, Williamson B, et al. Precipitating antibody in human serum to an antigen present in cultured Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A. 1966;56(6):1699-40. CrossRef
  6. Yip TT, Ngan RK, Lau WH, et al. A possible prognostic role of immunoglobulin G antibody against recombinant Epstein Barr virus BZLF1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer. 1994;74:2414-4. CrossRef
  7. Cheng HM, Foong YT, AbuSamah AJ, et al. Linear epitopes of the replication activator protein of Epstein Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma. Cancer Immunol Immunother. 1995;40:251-. CrossRef
  8. Teertstra HJ, Loo CE, van den Bosch MA, et al. Breast tomosynthesis in clinical practice: initial results. Eur Radiol. 2010;20:16-4. CrossRef
  9. Joab I, Nicolas JC, Schwaab G, et al. Detection of anti-Epstein Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer. 1991;48(5):647-. CrossRef
  10. Zeng Y, Nicolas JC, Schwaab G, et al. Detection of ZE BRA antibody in sera from patients with nasopharyngeal carcinoma infectious mononuc1eosis and Burkitt lymphoma. Bingdu Xuebao. 1992;8(3):218-2.
  11. Li D, Zeng Y, Cochet C, et al. Detection of IgG/ZEBRA antibodies in sera from patients with nas0pharyngeal carcinoma by ELISA methods. Bingdu Xuebao. 1994;10(1):78-0.
  12. Cao SM, Huang TB, Jian SW. The singnificance of EB virus ZEBRA/IgG in early diagnosis and prognosis of nasopharyngeal carcinoma (NPC). Aizheng. 1998;17(4):4-.
  13. Dardari R, Khyatti M, Benider A, et al. Antibodies to the Epstein–Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma [J]. Int J Cancer. 2000;86(1):71-.
  14. Cheng WM, Chen GX, Chen HI, et al. Assessment of nasopharyngeal carcinoma risk by EB virus antibody profile. Zhonghua Zhongliu Zazhi. 2002;24(6):45-.
  15. Chan KH, Gu YL, Ng F, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer. 2003;105(5):706-. CrossRef
  16. Gu YI, Zhang CQ, Wu ZB, et al. Study on sero diagnosis of nasopharyngeal carcinoma using a dual antibody test against recombinant Epstein Barr virus antigens. Aizheng. 2003;22(9):903-.
  17. Cheng WM, Ji MF, Li XL. Screening out nasopharyngeal carcinoma by two-stage ELISA for EB virus. Zhongguo Mianyixue Zazhi. 2003;19(12):834-.
  18. Zhang XM, Zhong JM, Tang MZ, et al. Comparison of IgA/VCA,IgA/EA,IgG/EA in immunoenzyme methods and ZEBRA EI ISA in early diagnosis of nasopharyngeal carcinoma. Zhonghua Shiyan He Linchuang Bingduxue Zazhi. 2006;20(3):263-.
  19. Zheng YM, Tang MZ, Li J, et al. Detection of EB virus ZEBRA/IgG antibody in nasopharyngeal carcinoma serum diagnosis. Huaxia Yixue. 2006;19(6):1092-.
  20. Ren J, Zhang XM, Zhang XG, et al. Studies on antibody response to recombinant Rta protein in patient with nasopharyngeal carcinoma. Zhonghua Weishengwuxue He Mianyixue Zazhi. 2006;26(11):1057-.
  21. Hu WW, Zong YS, Li FP, et al. Comparison of 6 antibody assays detecting Epstein-Barr virus for sero diagnosis of nasopharyngeal carcinoma. Zhongguo Zhongliu Linchuang. 2006;33(14):795-.
  22. Cheng WM, Ji MF, Li X, et al. Analysis of serum levels of antibodies against EBV EBNA1 and EB Zta in individuals in a nasopharyngeal carcinoma clan who have non nasopharyngeal carcinoma. Zhongguo Zhongliu Linchuang. 2007;34(21):1238-0.
  23. Yi X, Wu YY, Xie Y, et al. Antibody response to recombinant Epstein–Barr virus Zta protein in patients with nasopharyngeal carcinoma. Guangxi Yike Daxue Xuebao. 2007;24(3):365-.
  24. Liang YJ, Zong YS, Gu YI, et al. Application of enzyme-linked immunosorbent assay to the serological diagnosis of nasopharyngea1 carcinoma. Shiyong Yixue Zazhi. 2008;24(17):3055-.
  25. Jiang SQ, Liu Q. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of naspharyngea1 carcinoma. Aizheng. 2009;28(2):213-.
  26. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ Br Med J. 1997;315:980-. CrossRef
  27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. CrossRef
  28. Tian JH. Systematic review of diagnosis text accuracy. In: Yang KH, editor. System evaluation guideline. Beijing: People’s Medical Publishing House; 2010. p. 191-.
  29. Zhang TS, Zhong WZ. Meta-DiSc software in meta-analysis of diagnostic test. J Evid Based Med. 2008;8:97-08.
  30. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889-7. CrossRef
  31. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31. CrossRef
  32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ Br Med J. 2003;327:557-0. CrossRef
  33. Bowden J, Tierney JF, et al. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41. CrossRef
  34. Liu PL, Tang SS. Contrast enhanced ultrasound and contrast enhanced CT for diagnosis of focal pancreas lesions: a meta-analysis. Chin J Med Image Technol. 2011;27:2265-.
  35. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-5. CrossRef
  36. Higgins JPT, Green S (editors). (2011). Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions Version 5.1.0(updated March 2011). The Cochrane Collaboration. Available from www.cochrane-handbook.org.
  37. Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol. 2006;187:271-1. CrossRef
  38. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-5. CrossRef
  39. Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care. Meta-Analysis in context. London: BMJ Publishing Group; 2001. p. 248-2. CrossRef
  40. Jaeschke R, Guyatt G, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, editors. Users-guides to the medical literature. A manual for evidence-based clinical practice. Chicago: AMA Press; 2002. p. 121-0.
  
• 作者单位：Xiaoyan Zhang (1)
  Yun Zhang (1)
  Yunqiang Nie (2)
  Shoufeng Wang (1)
  Yanlin Chen (3)
  Dezhong Sun (3)
  
  1. Department of Medicine Oncology, Linyi City People’s Hospital, Linyi, 276000, China
  2. Department of Respiratory Medicine, Linyi City People’s Hospital, Linyi, 276000, China
  3. Department of Otolaryngology, Linyi City People’s Hospital, Linyi, 276000, China
  
• ISSN：1423-0380

文摘

The diagnosis of nasopharyngeal cancer (NPC) remains a clinical challenge. Many studies have assessed the diagnostic potential of Zta antibody of the Epstein–Barr virus (EBV) in NPC patients but with controversial results. This study aims to summarize the overall diagnostic performance of EBV Zta antibody in NPC. Based on a comprehensive search of the Pubmed and Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Wanfang Databases and China Citation Databases, we identified outcome data from all articles estimating diagnostic accuracy of EBV Zta antibody for NPC. A summary estimation for sensitivity, specificity, and other diagnostic indexes were pooled using a bivariate model. The overall measure of accuracy was calculated using summary receiver operating characteristic curve and the area under curve (AUC) was calculated. According to our inclusion criteria, 17 studies with 11,822 subjects (1,645 NPC cases, 10,177 controls) were included. The summary estimates were: sensitivity 0.87 (95?% confidence interval [CI]--.86-.89), specificity 0.94 (95?% CI--.93-.94), positive likelihood ratio 8.05 (95?% CI--.59-1.59), negative likelihood ratio 0.16 (95?% CI--.12-.21), diagnostic odds ratio 52.93 (95?% CI--9.95-3.56), the AUC and Q* index were 0.9352 and 0.8714, respectively. In conclusion, serum EBV Zta had a better diagnostic performance for NPC. Further studies should be performed to confirm our findings.